You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 23, 2024

CLINICAL TRIALS PROFILE FOR PENICILLAMINE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for PENICILLAMINE

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00003751 ↗ Penicillamine, Low Copper Diet, and Radiation Therapy in Treating Patients With Glioblastoma Completed National Cancer Institute (NCI) Phase 2 1999-03-01 RATIONALE: Penicillamine may stop the growth of glioblastomas by stopping blood flow to the tumor. A diet low in copper may interfere with the growth of brain tumor cells. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining these therapies may be effective in treating glioblastoma. PURPOSE: Phase II trial to study the effectiveness of penicillamine, a low copper diet, and radiation therapy in treating patients who have newly diagnosed glioblastoma.
NCT00003751 ↗ Penicillamine, Low Copper Diet, and Radiation Therapy in Treating Patients With Glioblastoma Completed Sidney Kimmel Comprehensive Cancer Center Phase 2 1999-03-01 RATIONALE: Penicillamine may stop the growth of glioblastomas by stopping blood flow to the tumor. A diet low in copper may interfere with the growth of brain tumor cells. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining these therapies may be effective in treating glioblastoma. PURPOSE: Phase II trial to study the effectiveness of penicillamine, a low copper diet, and radiation therapy in treating patients who have newly diagnosed glioblastoma.
NCT00003751 ↗ Penicillamine, Low Copper Diet, and Radiation Therapy in Treating Patients With Glioblastoma Completed Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Phase 2 1999-03-01 RATIONALE: Penicillamine may stop the growth of glioblastomas by stopping blood flow to the tumor. A diet low in copper may interfere with the growth of brain tumor cells. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining these therapies may be effective in treating glioblastoma. PURPOSE: Phase II trial to study the effectiveness of penicillamine, a low copper diet, and radiation therapy in treating patients who have newly diagnosed glioblastoma.
NCT00161148 ↗ Probiotics in Patients With Primary Sclerosing Cholangitis Unknown status UMC Utrecht Phase 3 2005-01-01 PSC is a progressive liver disease without effective medical treatment. There is often co-existent ulcerative colitis. Probiotics (bacterial food supplements) have been shown to benefit patients with ulcerative colitis. In the current protocol potential beneficial effects of probiotics on liver biochemistry and liver related symptoms as pruritus are being assessed in 12 PSC patients in a randomized controlled cross over study (3 months probiotics, 1 one wash-out and 3 months placebo).
NCT00212355 ↗ Efficacy and Safety, Long-term Study of Zinc Acetate to Treat Wilson's Disease in Japan. Completed Nobelpharma Phase 3 2005-03-01 The purpose of this long-term study is to determine whether Zinc Acetate is effective and safe in the treatment of Wilson's disease among Japanese.
NCT00246064 ↗ The Infliximab Rheumatoid Arthritis Methotrexate Tapering (iRAMT) Protocol Completed Centocor Ortho Biotech Services, L.L.C. Phase 4 2001-12-01 The purpose of the study was to evaluate the ability of a maintenance dosage regimen of infliximab to achieve and sustain at least 40% improvement from baseline in the total joint count in patients with active Rheumatoid Arthritis (RA) during methotrexate tapering.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for PENICILLAMINE

Condition Name

Condition Name for PENICILLAMINE
Intervention Trials
Wilson Disease 4
Wilson's Disease 2
Scleroderma 2
Systemic Sclerosis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for PENICILLAMINE
Intervention Trials
Hepatolenticular Degeneration 6
Scleroderma, Systemic 2
Arthritis, Rheumatoid 2
Scleroderma, Diffuse 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for PENICILLAMINE

Trials by Country

Trials by Country for PENICILLAMINE
Location Trials
United States 31
United Kingdom 4
China 3
Poland 3
Germany 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for PENICILLAMINE
Location Trials
Connecticut 3
Texas 3
Pennsylvania 3
New York 2
California 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for PENICILLAMINE

Clinical Trial Phase

Clinical Trial Phase for PENICILLAMINE
Clinical Trial Phase Trials
Phase 4 3
Phase 3 4
Phase 2/Phase 3 1
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for PENICILLAMINE
Clinical Trial Phase Trials
Completed 9
Recruiting 2
Active, not recruiting 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for PENICILLAMINE

Sponsor Name

Sponsor Name for PENICILLAMINE
Sponsor Trials
New York University School of Medicine 1
Assistance Publique - Hôpitaux de Paris 1
NYU Langone Health 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for PENICILLAMINE
Sponsor Trials
Industry 12
Other 11
NIH 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.